Moderna, Inc. Common Stock
MRNA Real Time Price USDRecent trades of MRNA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MRNA's directors and management
Government lobbying spending instances
-
$10,000 Oct 18, 2024 Issue: Health Issues
-
$80,000 Sep 18, 2024 Issue: Foreign Relations Health Issues
-
$50,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$45,000 Jul 22, 2024 Issue: Health Issues
-
$80,000 Jul 16, 2024 Issue: Foreign Relations Health Issues
-
$30,000 Jul 15, 2024 Issue: Taxation/Internal Revenue Code
-
$40,000 Apr 17, 2024 Issue: Medicare/Medicaid
-
$50,000 Jan 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$45,000 Jan 22, 2024 Issue: Health Issues
-
$30,000 Jan 11, 2024 Issue: Taxation/Internal Revenue Code
-
$45,000 Oct 20, 2023 Issue: Health Issues
-
$50,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$45,000 Jul 20, 2023 Issue: Health Issues
-
$80,000 Jul 19, 2023 Issue: Foreign Relations Health Issues
-
$50,000 Jul 19, 2023 Issue: Medicare/Medicaid Health Issues
-
$45,000 Apr 20, 2023 Issue: Health Issues
-
$50,000 Apr 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 18, 2023 Issue: Foreign Relations Health Issues
-
$80,000 Jan 20, 2023 Issue: Foreign Relations Health Issues
-
$50,000 Jan 20, 2023 Issue: Health Issues
-
$45,000 Jan 20, 2023 Issue: Health Issues
-
$45,000 Oct 20, 2022 Issue: Health Issues
-
$50,000 Oct 20, 2022 Issue: Health Issues
-
$70,000 Oct 19, 2022 Issue: Foreign Relations Health Issues
-
$50,000 Jul 20, 2022 Issue: Health Issues
-
$45,000 Jul 20, 2022 Issue: Health Issues
-
$80,000 Jul 18, 2022 Issue: Foreign Relations Health Issues
-
$50,000 Apr 20, 2022 Issue: Health Issues
-
$80,000 Apr 20, 2022 Issue: Foreign Relations Health Issues
-
$45,000 Apr 20, 2022 Issue: Health Issues
-
$30,000 Jan 20, 2022 Issue: Health Issues
-
$50,000 Jan 19, 2022 Issue: Foreign Relations Health Issues
-
$50,000 Jan 19, 2022 Issue: Health Issues
-
$50,000 Oct 20, 2021 Issue: Health Issues
-
$30,000 Oct 20, 2021 Issue: Health Issues
-
$50,000 Oct 19, 2021 Issue: Foreign Relations Health Issues
-
$50,000 Jul 20, 2021 Issue: Health Issues
-
$30,000 Jul 20, 2021 Issue: Health Issues
-
$50,000 Jul 19, 2021 Issue: Pharmacy Foreign Relations Health Issues
-
$30,000 Apr 20, 2021 Issue: Health Issues
-
$50,000 Apr 20, 2021 Issue: Health Issues
-
$30,000 Apr 20, 2021 Issue: Health Issues
-
$50,000 Apr 20, 2021 Issue: Pharmacy Health Issues
-
$50,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$50,000 Jul 20, 2020 Issue: Health Issues
-
$20,000 Jul 20, 2020 Issue: Health Issues
-
$10,000 Apr 20, 2020 Issue: Health Issues
-
$30,000 Oct 21, 2019 Issue: Health Issues
-
$10,000 Jul 22, 2019 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
Federal grants, loans, and purchases
- $17,182 2024-05-30 00:00:00 Agency: Department of Health and Human Services
- $8,161 2024-05-30 00:00:00 Agency: Department of Health and Human Services
- $0 2024-01-03 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-06-21 00:00:00 Agency: Department of Veterans Affairs
- $17,182 2023-06-14 00:00:00 Agency: Department of Health and Human Services
- $8,161 2023-06-13 00:00:00 Agency: Department of Health and Human Services
- $0 2022-09-30 00:00:00 Agency: DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Estimated quarterly amount awarded from public contracts
Number of mentions of MRNA in WallStreetBets Daily Discussion
Recent insights relating to MRNA
Recent picks made for MRNA stock on CNBC
ETFs with the largest estimated holdings in MRNA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MRNA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.